ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / LTGO / dividends
SVRA (35) MLTX (36) JANX (41) RIGL (75) ⌘ Pro Terminal →

Latigo Biotherapeutics Inc. (LTGO) Dividend Safety Gauge & 10-Year DRIP Compounder

$13.95 -10.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.67

Latigo Biotherapeutics Inc. (LTGO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • SELL / AVOID Cap $1.03B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LTGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $13.95 (-10.23% 1D, market cap $1.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LTGO ranks #456 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LTGO compare to SVRA and MLTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SVRA (Savara Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LTGO?
▼

Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.67 (-2.03%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (5)SEC (13)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$27 Bull$13 Base$10 Bear
📬 FREE LTGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LTGO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY LTGO SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0.7% FCF Margin ($28.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$16.02-10.7% Next Q
Q2 (-2Q)
48
Grade D$14.30+6.7% Next Q
Q3 (-1Q)
46
Grade D$15.26-8.6% Next Q
Current
43
Grade D-$13.95-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LTGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LTGO currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.78) and Max Pain ($14.65) forces dealer call-delta covering toward $27.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LTGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LTGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LTGO)

  • ✓Walkthrough of LTGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LTGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.56%▼ DESCENDING CHANNEL
2026-11-02O $15.83H $15.83L $13.95C $13.95VOL 141.7K
RES: $22.46SUP: $11.02SMA50: $18.78SMA200: $18.97
$26.80$23.20$19.59$15.99$12.38RES $22.46SUP $11.02$13.952026-08-072026-08-282026-09-212026-10-122026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LTGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LTGO Butterfly Map → + Track LTGO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LTGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LTGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LTGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LTGO)

Health Care Rank #456 of 1016 ⚔️ SVRA vs LTGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LTGO vs. SVRA, MLTX, JANX, RIGL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Latigo Biotherapeutics Inc. (LTGO) ranks #456 by composite RQD confidence (43/100, grade D-) and #358 by equity capitalization ($1.03B). Within this direct 5-issuer industry benchmark cohort, LTGO leads on earnings valuation at N/A trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with LTGO at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LTGO ACTIVE
Latigo Biotherapeutics Inc.
D- 43/100 — — — -10.23% $1.03B Benchmark Subject
SVRA
Savara Inc.
D- 35/100 — — -35.0% -2.63% $1.02B /svra-vs-ltgo →
MLTX
MoonLake Immunotherapeutics (Class A)
D- 36/100 — — -35.0% -6.28% $1.07B /mltx-vs-ltgo →
JANX
Janux Therapeutics Inc.
D- 41/100 — — -13.8% -2.02% $1.09B /janx-vs-ltgo →
RIGL
Rigel Pharmaceuticals Inc.
B 75/100 — 93.3% 28.2% -0.27% $961.1M /rigl-vs-ltgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002056611

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Latigo Biotherapeutics Inc. (LTGO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LTGO closed FY2025 with $75.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 $0 — — $75.5M —

3. LTGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LTGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $13.95 (-10.23% 1D, market cap $1.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LTGO ranks #456 in composite RQD confidence.

How does LTGO compare to SVRA and MLTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LTGO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SVRA (Savara Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, LTGO leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LTGO?

Per LTGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002056611), Latigo Biotherapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $75.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LTGO trading relative to its 50-day, 200-day, and 52-week technical levels?

LTGO last traded at $13.95 (-10.23% on volume of 216,180 shares), positioning the stock -25.72% below its 50-day simple moving average ($18.78) and -26.46% below its 200-day simple moving average ($18.97). Across its 52-week range of $13.50 to $25.93, LTGO sits at the 3.6% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.21 to $15.69).

LTGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does LTGO pay a dividend and is it safe?

Latigo Biotherapeutics Inc. (LTGO) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: LTGO RQD Cockpit LTGO 12M Forecast LTGO Earnings & Move LTGO Dividends & DRIP LTGO Insiders & 13F LTGO Whale Options LTGO Profit Sankey LTGO News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LTGO — Latigo Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:16Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LTGO scores 43 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

  • Fundamental Cash Engine (10 / 20): Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash-flow yield to support the current valuation from operations.
  • Whale 13F Flow (5 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the lowest-scoring pillar, indicating weak institutional support in the source data. Holder-level detail is not available in source data.
  • Insider Conviction (9 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score indicates limited insider-conviction signal.
  • Macro Regime Fit (6 / 20): Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 implies market-level sensitivity; the low score reflects weak fit with the current regime as measured by the rating model.
  • Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the highest-scoring pillar and represents the relative strength of the company's balance sheet in the source data.

Investor implications: The composite score is driven by zero reported ROIC and FCF yield, weak institutional flow, and limited insider conviction, partially offset by a comparatively stronger balance-sheet profile. A prospective investor evaluating the stock today would need to weigh a valuation with no operating-cash-return support against a balance sheet the rating model rates as moderately sound.

Business

Latigo Biotherapeutics Inc. is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the company profile, the issuer has a market capitalization of $1.0B. Specific products, customers, and revenue model details are not available in source data. Per the SEC financials, reported revenue for FY 2025 is $0.0M.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$0.0M$0.0M$0.0MN/AN/A$69.4MN/A

Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with gross, operating, and net margins each at 0% per the market data. Per the Roarable RQD rating, ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. Reported cash is $69.4M per the SEC financials; debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference LTGO, all flagged with a YELLOW light and MARKET WIRE impact label. Headlines reference the company's stock price and news coverage, a NaV1.8 market commentary piece suggesting the company "May Be The One To Profit From It," an estimates report, a report of the stock hitting a new 12-month low, and a report of shares rising 5.5%. Per the market data, the stock is down 1.83% on the session, and the 52-week range runs from $13.5 to $25.93. The feed contains no specific clinical, regulatory, or commercial catalyst details beyond these headlines. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Risk watch: The new 12-month low headline, sitting alongside a price near the bottom of the 52-week range, is the most directly relevant risk item in the feed.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is recorded as NONE, with no upstream or downstream links and no proprietary signals. Upstream/downstream dependencies, sector correlations beyond the stated sector and industry, and second-order bottlenecks are not available in source data.

Open Questions

  • What are the company's specific pipeline assets and development milestones, given the source data lists no revenue and no operating income?
  • What is the nature of the reported $69.4M cash position relative to the cash burn implied by zero revenue and zero operating income?
  • What is the debt balance, since debt is listed as N/A despite a reported Debt/Equity of 0.5?
  • What is the basis for the "NaV1.8 market" commentary and does it reflect any specific program or partnership?
  • Who holds the shares, given that holder data is not available in source data?

LTGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Latigo Biotherapeutics Inc. (LTGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LTGO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LTGO Bull vs. Bear Conversation Board — What's Your Call at $13.95?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LTGO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on LTGO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $13.68 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LTGO (D- • RQD 43/100) a Buy at $15.54?

Welcome to the LTGO (Latigo Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.12 (-22.0%)
Spot @ $15.54

Pump the brakes on LTGO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LTGO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Latigo Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $17.87 (+15.0%)
Spot @ $15.54

LTGO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LTGO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.54 (52-wk range $13.50 - $25.93), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%